BCMA– tag –
-
Tempest Therapeutics Licenses Senlang’s In Vivo CAR-T Platform, Targeting Relapsed/Refractory Multiple Myeloma with Dual BCMA/GPRC5D Approach in Phase I Trial
AllSci USA Overview Tempest Therapeutics has secured an exclusive license option for Hebei Senlang Biotechnology's CD7-targeting lentiviral in vivo CAR-T platform and related product candidates. This platform generates CAR-T and CAR-NK c... -
Analysis Group Study: Early CAR-T Therapy Ciltacabtagene Autoleucel Achieves 98.0% Overall Response Rate with Favorable Real-World Outcomes in Relapsed/Refractory Multiple Myeloma
Analysis Group USA Overview An Analysis Group study revealed that early-line CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), demonstrated favorable real-world outcomes in relapsed or refractory multiple myeloma (RRMM) patients... -
Allogeneic BCMA CAR T Therapy CB-011 Achieves Deep Responses and Confirms Immune Cloaking in Multiple Myeloma Phase 1 Trial
The ASCO Post USA Overview CB-011, the first allogeneic anti-BCMA CAR T-cell therapy incorporating immune cloaking technology, achieved a high overall response rate (ORR) in its Phase 1 CaMMouflage trial for relapsed/refractory heavily p... -
Kelonia Therapeutics’ BCMA-Targeted In Vivo CAR T Therapy KLN-1010 Shows Promise for Multiple Myeloma with Updated Phase 1 ASCO Data
Kelonia Therapeutics Press Release USA Overview Kelonia Therapeutics presented updated first-in-human data from its Phase 1 inMMyCAR study of KLN-1010, a BCMA-targeted in vivo CAR T-cell therapy, at the 2026 American Society of Clinical ...
1